(Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its ...

Genetic changes are a significant cause of infertility, impacting over 15% of the global population. TLE6, a major protein ...

We are excited to welcome Eric to our Board of Directors,” said Brian C. Thomas, PhD, CEO and founder of Metagenomi. “His tremendous track record in the pharmaceutical industry as well as his ...

The de-extinction company led by CEO Ben Lamm has raked in $435 million in funding since its launch. He believes it has ...

Bank of America Securities analyst Alec Stranahan maintained a Sell rating on Editas Medicine (EDIT – Research Report) yesterday and set a ...

The adenine base editor corrected the most common mutation associated with Stargardt disease in the ABCA4 gene with no off-target effects.

Genome editing is an exciting but still nascent field, and companies in the area face as many obstacles as they do opportunities. Sangamo CEO Sandy Macrae told us how his company is being cautious ...

Panelists from China, India, and Vietnam speak about the threat the fungal disease poses on each country and the best ...

Tune Therapeutics, an epigenome-editing company with origins at Duke University, has raised over $175 million in financing to advance a potential treatment for chronic hepatitis B and other diseases.

It was an extremely busy week in the biotech sector, with several companies making important presentations at the J.P. Morgan ...

To prepare students for the challenges and opportunities of an increasingly AI-driven world, Connecticut College has launched ...

In the face of ever-changing environmental conditions, plants are constantly challenged by various stressors. Understanding ...